{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:16Z","timestamp":1792723096052,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01066","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:38:16Z","timestamp":1789666696000},"page":"e01066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cUpdates on diagnostic and prognostic molecular biomarkers of CNS tumors\u201d"],"prefix":"10.1016","volume":"23","author":[{"given":"Shane","family":"Eaton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Almotairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e01066_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2026.e01066_bib4","article-title":"cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics","volume":"7","author":"Aldape","year":"2025","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.neurot.2026.e01066_bib5","article-title":"Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors\u2014A prospective study and guidelines for clinical testing","volume":"5","author":"Galbraith","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.neurot.2026.e01066_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.70035","article-title":"cIMPACT-NOW update 11: proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors","volume":"36","author":"Wesseling","year":"2026","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib8","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/neuonc\/noag108","article-title":"cIMPACT-NOW update 12: refining pathology-based risk stratification and grading for IDH-mutant gliomas","volume":"28","author":"Brat","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.70018","article-title":"cIMPACT-NOW update 10: recommendations for defining new types for central nervous system tumor classification","volume":"35","author":"Hawkins","year":"2025","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noag069","article-title":"Expanding the molecular grading criteria in IDH-mutant astrocytoma","author":"Virata","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/neuonc\/noaa258","article-title":"IDH-Wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification","volume":"23","author":"Berzero","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-024-02773-3","article-title":"IDH-Wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4","volume":"148","author":"Priesterbach-Ackley","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-023-02674-x","article-title":"Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas","volume":"147","author":"Pohl","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","article-title":"Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome","volume":"134","author":"Panwalkar","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-020-01056-8","article-title":"EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression","volume":"8","author":"Antin","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01066_bib33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/neuonc\/noab034","article-title":"Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q","volume":"23","author":"Baroni","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00401-021-02300-8","article-title":"TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma","volume":"141","author":"Thomas","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib67","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jnen\/nlz064","article-title":"Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior","volume":"78","author":"Swanson","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurot.2026.e01066_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00401-023-02668-9","article-title":"Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation","volume":"147","author":"Neyazi","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neurot.2026.e01066_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111162","article-title":"Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development","volume":"40","author":"Williamson","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2026.e01066_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","article-title":"Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of group 3 and group 4 subtypes","volume":"138","author":"Sharma","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01066_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40478-023-01652-4","article-title":"Subtyping of group 3\/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese pediatric molecular neuro-oncology group study","volume":"11","author":"Fukuoka","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01066_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-022-02522-4","article-title":"Identification of low and very high-risk patients with non-WNT\/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts","volume":"145","author":"Mynarek","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib50","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/neuonc\/noz244","article-title":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid\/rhabdoid tumors","volume":"22","author":"Fr\u00fchwald","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bpa.12413","article-title":"Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome","volume":"27","author":"Johann","year":"2017","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib55","first-page":"14","article-title":"FOXR2-activated CNS neuroblastoma: characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression","volume":"2","author":"Ji","year":"2026","journal-title":"NEUPED"},{"key":"10.1016\/j.neurot.2026.e01066_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4132\/jptm.2025.07.23","article-title":"Central nervous system tumors with BCOR internal tandem duplications: a systematic review of clinical, radiological, and pathological features in 69 cases","volume":"59","author":"Lee","year":"2025","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.neurot.2026.e01066_bib57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s43018-025-00964-9","article-title":"Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor\u2013ligand interactions","volume":"6","author":"Beck","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.neurot.2026.e01066_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdag086","article-title":"Genetic landscape and molecular targets in pediatric pineal tumors","author":"Pasquinelli","year":"2026","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.neurot.2026.e01066_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40478-025-02140-7","article-title":"Recurrent genetic alterations in epigenetically defined pineoblastoma subtypes","volume":"13","author":"Goschzik","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01066_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jmoldx.2022.04.009","article-title":"Validation of whole genome methylation profiling classifier for central nervous system tumors","volume":"24","author":"Santana-Santos","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.neurot.2026.e01066_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-023-02255-1","article-title":"Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology","volume":"29","author":"Sturm","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01066_bib12","first-page":"459","article-title":"DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas","volume":"138","author":"Korshunov","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00401-012-1077-2","article-title":"DNA methylation profiling of medulloblastoma allows robust sub-classification and improved outcome prediction using formalin-fixed biopsies","volume":"125","author":"Schwalbe","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bpa.12866","article-title":"cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors","volume":"30","author":"Ellison","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.neurot.2026.e01066_bib19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/PAS.0000000000002118","article-title":"A novel type of IDH-Wildtype glioma characterized by gliomatosis cerebri-like growth pattern, TERT promoter mutation, and distinct epigenetic profile","volume":"1","author":"Muench","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","article-title":"Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system","volume":"126","author":"Koelsche","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00401-017-1710-1","article-title":"H3-\/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers","volume":"134","author":"Korshunov","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2025.108536","article-title":"The landscape of FGFR-TACC fusion in adult glioblastoma: from bench to bedside","volume":"795","author":"Liu","year":"2025","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.neurot.2026.e01066_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10014-023-00468-3","article-title":"Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity","volume":"40","author":"Bender","year":"2023","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-020-02243-6","article-title":"Primary mismatch repair deficient IDH-mutant astrocytoma is a distinct type with a poor prognosis","volume":"141","author":"Suwala","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib25","article-title":"De novo replication repair deficient glioblastoma, IDH-wildtype, is a distinct glioblastoma subtype in adults that May benefit from immune checkpoint blockade","volume":"147","author":"Hadad","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1470-2045(24)00640-5","article-title":"The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study","volume":"26","author":"Negm","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41588-025-02420-x","article-title":"Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma","volume":"58","author":"Fernandez","year":"2026","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurot.2026.e01066_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41374-021-00694-3","article-title":"Sporadic and lynch syndrome-associated mismatch repair-deficient brain tumors","volume":"102","author":"Kim","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.neurot.2026.e01066_bib29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1200\/JCO.21.02873","article-title":"Genomic microsatellite signatures identify germline mismatch repair deficiency and risk of cancer onset","volume":"41","author":"Chung","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3174\/ajnr.A8237","article-title":"Ependymal tumors: overview of the recent world health organization histopathologic and genetic updates with an imaging characteristic","volume":"45","author":"Soni","year":"2024","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2026.e01066_bib37","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11912-022-01260-w","article-title":"Ependymoma: evaluation and management updates","volume":"24","author":"Rud\u00e0","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.neurot.2026.e01066_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jmp6030023","article-title":"The current landscape of molecular pathology for the diagnosis and treatment of ependymoma","volume":"6","author":"Steller","year":"2025","journal-title":"J Mol Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00401-025-02866-7","article-title":"Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to Distinguish myxopapillary ependymoma from spinal ependymoma","volume":"149","author":"Purkait","year":"2025","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib40","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-14-2650","article-title":"Spinal myxopapillary ependymomas demonstrate a warburg phenotype","volume":"21","author":"Mack","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01066_bib41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","article-title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","volume":"26","author":"Groff","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib42","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00401-021-02351-x","article-title":"Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas","volume":"142","author":"Kirches","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/neuonc\/noaf252","article-title":"Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology","volume":"28","author":"Yefet","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/jmp6020011","article-title":"The current landscape of molecular pathology for the diagnosis and treatment of pediatric medulloblastoma","volume":"6","author":"Koch","year":"2025","journal-title":"J Mol Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/neuonc\/noz235","article-title":"Molecular subgrouping of atypical teratoid\/rhabdoid Tumors\u2014A reinvestigation and current consensus","volume":"22","author":"Ho","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01066_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/nop\/npad005","article-title":"Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)","volume":"10","author":"Tran","year":"2023","journal-title":"Neuro-Oncol Pract"},{"key":"10.1016\/j.neurot.2026.e01066_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jmp6020013","article-title":"The current landscape of molecular pathology for the diagnosis and treatment of atypical teratoid rhabdoid tumor","volume":"6","author":"Childress","year":"2025","journal-title":"J Mol Pathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ccell.2019.10.008","article-title":"Clonally expanded T cells reveal immunogenicity of rhabdoid tumors","volume":"36","author":"Leruste","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neurot.2026.e01066_bib59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00401-023-02638-1","article-title":"Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics","volume":"146","author":"Rahmanzade","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00401-021-02356-6","article-title":"Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors","volume":"142","author":"Sievers","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40478-023-01695-7","article-title":"CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas","volume":"12","author":"Tauzi\u00e8de-Espariat","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01066_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00401-023-02558-0","article-title":"Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions","volume":"145","author":"Bogumil","year":"2023","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00401-021-02354-8","article-title":"PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum","volume":"142","author":"Alhalabi","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurot.2026.e01066_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40478-023-01523-y","article-title":"CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population","volume":"11","author":"Tauzi\u00e8de-Espariat","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01066_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-023-01549-2","article-title":"Clinicopathological and molecular characterization of a case classified by DNA-Methylation profiling as \u201cCNS embryonal tumor with BRD4-LEUTX fusion.\u201d","volume":"18","author":"Lebrun","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2026.e01066_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s42003-025-07681-0","article-title":"Double and single stranded detection of 5-methylcytosine and 5-hydroxymethylcytosine with nanopore sequencing","volume":"8","author":"Halliwell","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.neurot.2026.e01066_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/17501911.2025.2586452","article-title":"5mC and 5hmC methylation sequencing: the power of 6-base sequencing in a multiomic era","volume":"18","author":"Crawford","year":"2026","journal-title":"Epigenomics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:53:45Z","timestamp":1792720425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002369"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01066","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cUpdates on diagnostic and prognostic molecular biomarkers of CNS tumors\u201d","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01066"}}